Ben Tre Pharmaceutical JSC (HOSE:DBT)
Vietnam
· Delayed Price · Currency is VND 11,400
+250 (2.24%)
At close: Apr 28, 2026
HOSE:DBT Income Statement
Financials in millions VND. Fiscal year is January - December.
Millions VND. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2019 | FY 2018 | 2017 - 2013 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Jan '25 Jan 1, 2025 | Dec '23 Dec 31, 2023 | Dec '19 Dec 31, 2019 | Dec '18 Dec 31, 2018 | 2017 - 2013 |
| Revenue | 860,313 | 868,411 | 811,616 | 800,500 | 809,914 | Upgrade
|
| Revenue Growth (YoY) | -0.93% | 7.00% | 1.39% | -1.16% | 1.23% | Upgrade
|
| Cost of Revenue | 521,866 | 522,309 | 502,000 | 615,255 | 628,852 | Upgrade
|
| Gross Profit | 338,447 | 346,103 | 309,616 | 185,245 | 181,063 | Upgrade
|
| Selling, General & Admin | 293,421 | 296,991 | 242,522 | 155,629 | 153,771 | Upgrade
|
| Operating Expenses | 293,421 | 296,991 | 242,522 | 155,629 | 153,771 | Upgrade
|
| Operating Income | 45,026 | 49,112 | 67,094 | 29,616 | 27,292 | Upgrade
|
| Interest Expense | -40,651 | -40,113 | -39,533 | -15,184 | -13,210 | Upgrade
|
| Interest & Investment Income | 6,804 | 8,517 | 3,380 | 8,982 | 4,607 | Upgrade
|
| Earnings From Equity Investments | - | - | 1,000 | 5,829 | 5,584 | Upgrade
|
| Currency Exchange Gain (Loss) | -2,019 | -537.72 | 193.37 | - | - | Upgrade
|
| Other Non Operating Income (Expenses) | 655.87 | 1,532 | -2,045 | 592.9 | 2,352 | Upgrade
|
| EBT Excluding Unusual Items | 9,816 | 18,510 | 30,090 | 29,836 | 26,625 | Upgrade
|
| Gain (Loss) on Sale of Investments | -200.81 | - | -9,121 | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | 14,393 | 1,870 | 2,126 | - | - | Upgrade
|
| Pretax Income | 24,008 | 20,380 | 23,095 | 29,836 | 26,625 | Upgrade
|
| Income Tax Expense | 9,608 | 8,127 | 5,629 | 5,715 | 5,172 | Upgrade
|
| Earnings From Continuing Operations | 14,400 | 12,253 | 17,466 | 24,121 | 21,453 | Upgrade
|
| Minority Interest in Earnings | -197.41 | 2,328 | -1,271 | -2,725 | -1,260 | Upgrade
|
| Net Income | 14,203 | 14,581 | 16,195 | 21,396 | 20,193 | Upgrade
|
| Preferred Dividends & Other Adjustments | 1,354 | 1,381 | 3,230 | - | - | Upgrade
|
| Net Income to Common | 12,849 | 13,200 | 12,964 | 21,396 | 20,193 | Upgrade
|
| Net Income Growth | -2.59% | -9.97% | -24.31% | 5.96% | -29.73% | Upgrade
|
| Shares Outstanding (Basic) | 21 | 19 | 17 | - | - | Upgrade
|
| Shares Outstanding (Diluted) | 21 | 19 | 17 | - | - | Upgrade
|
| Shares Change (YoY) | 11.98% | 9.97% | - | - | - | Upgrade
|
| EPS (Basic) | 614.08 | 706.40 | 762.96 | - | - | Upgrade
|
| EPS (Diluted) | 614.00 | 706.40 | 762.62 | - | - | Upgrade
|
| EPS Growth | -13.08% | -7.37% | - | - | - | Upgrade
|
| Free Cash Flow | -13,630 | -40,869 | -6,956 | -80,940 | -21,328 | Upgrade
|
| Free Cash Flow Per Share | -651.41 | -2187.12 | -409.38 | - | - | Upgrade
|
| Gross Margin | 39.34% | 39.86% | 38.15% | 23.14% | 22.36% | Upgrade
|
| Operating Margin | 5.23% | 5.66% | 8.27% | 3.70% | 3.37% | Upgrade
|
| Profit Margin | 1.49% | 1.52% | 1.60% | 2.67% | 2.49% | Upgrade
|
| Free Cash Flow Margin | -1.58% | -4.71% | -0.86% | -10.11% | -2.63% | Upgrade
|
| EBITDA | 62,675 | 66,221 | 75,979 | 42,952 | 40,299 | Upgrade
|
| EBITDA Margin | 7.29% | 7.63% | 9.36% | 5.37% | 4.98% | Upgrade
|
| D&A For EBITDA | 17,649 | 17,109 | 8,884 | 13,336 | 13,007 | Upgrade
|
| EBIT | 45,026 | 49,112 | 67,094 | 29,616 | 27,292 | Upgrade
|
| EBIT Margin | 5.23% | 5.66% | 8.27% | 3.70% | 3.37% | Upgrade
|
| Effective Tax Rate | 40.02% | 39.88% | 24.37% | 19.15% | 19.43% | Upgrade
|
| Revenue as Reported | 860,313 | 868,411 | 811,616 | 800,500 | 809,914 | Upgrade
|
| Advertising Expenses | - | - | 6,704 | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.